SL Science Holding Limited Reports First Half 2026 Financial Results

What happened

SL Science Holding Limited reported first half 2026 net revenue up 23% to $1.39 million, with gross margin expanding to 40.2%. Growth came from B2B distribution and lower purchase costs after stable supplier relationships secured favorable procurement terms.

Confirmed

Global impact / market context

Higher revenue and a 40.2% gross margin mean the company keeps more profit per sale, which helps fund clinical programs. The $7.8 million PIPE financing, which means money raised from private investors, adds cash available after listing.

Analyst inference

The company shifted from direct retail to B2B wholesale distribution in Taiwan, making sales volumes more predictable and supplier pricing better. Its June Nasdaq listing and concurrent $7.8 million PIPE financing gave it capital to advance cellular and gene therapy programs.

Analyst inference

What to watch

1. Watch whether the 23% revenue growth and 40.2% gross margin continue in later periods, since the reported figures cover only the six months ended June 30, 2026 and are unaudited. Confirmed
2. Management intends to use its capitalization, including the $7.8 million PIPE financing, to advance clinical programs, so investors should look for future disclosure on how that capital is spent. Proposed
3. The B2B wholesale model's benefits depend on stable supplier relationships and favorable procurement terms, so any change in supplier pricing or volume predictability could pressure revenue and profit per sale. Analyst inference

Evidence

• globenewswire.com